- Home
- KRC vs GRFS Comparison
KRC vs GRFS Comparison
Compare KRC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRC
- GRFS
- Stock Information
- Founded
- KRC 1947
- GRFS 1940
- Country
- KRC United States
- GRFS Spain
- Employees
- KRC 248
- GRFS N/A
- Industry
- KRC Real Estate Investment Trusts
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- KRC Real Estate
- GRFS Health Care
- Exchange
- KRC Nasdaq
- GRFS Nasdaq
- Market Cap
- KRC 4.8B
- GRFS 5.5B
- IPO Year
- KRC 1997
- GRFS 2006
- Fundamental
- Price
- KRC $40.53
- GRFS $7.51
- Analyst Decision
- KRC Hold
- GRFS Strong Sell
- Analyst Count
- KRC 8
- GRFS 1
- Target Price
- KRC $40.63
- GRFS N/A
- AVG Volume (30 Days)
- KRC 1.2M
- GRFS 1.3M
- Earning Date
- KRC 02-03-2025
- GRFS 01-01-0001
- Dividend Yield
- KRC 5.33%
- GRFS N/A
- EPS Growth
- KRC N/A
- GRFS N/A
- EPS
- KRC 1.67
- GRFS 0.27
- Revenue
- KRC $1,118,266,000.00
- GRFS $7,814,096,584.00
- Revenue This Year
- KRC N/A
- GRFS $8.86
- Revenue Next Year
- KRC $0.09
- GRFS $7.00
- P/E Ratio
- KRC $24.25
- GRFS $33.24
- Revenue Growth
- KRC N/A
- GRFS 7.21
- 52 Week Low
- KRC $30.71
- GRFS $5.30
- 52 Week High
- KRC $43.78
- GRFS $12.15
- Technical
- Relative Strength Index (RSI)
- KRC 49.87
- GRFS 44.79
- Support Level
- KRC $38.39
- GRFS $7.41
- Resistance Level
- KRC $42.55
- GRFS $8.13
- Average True Range (ATR)
- KRC 1.27
- GRFS 0.31
- MACD
- KRC -0.19
- GRFS 0.06
- Stochastic Oscillator
- KRC 51.44
- GRFS 45.13
About KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.